Trials / Completed
CompletedNCT05467943
Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Tazemetostat for the Treatment of Patients With Relapsed/Refractory Follicular Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Hutchmed · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Treating Relapsed/Refractory Follicular Lymphoma with Tazemetostat
Detailed description
This is an open-label, monotherapy, Phase II Study clinical study. The objective is to evaluate the efficacy, safety, and pharmacokinetics of Tazemetostat in the treatment of patients with relapsed/refractory follicular lymphoma. It is planned to enroll 39 Chinese patients in 2 cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tazemetostat | All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle |
Timeline
- Start date
- 2022-07-29
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
- First posted
- 2022-07-21
- Last updated
- 2025-01-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05467943. Inclusion in this directory is not an endorsement.